May 5, 2017 / 11:41 AM / 5 months ago

BRIEF-TG Therapeutics Inc's qtrly loss per share $0.52

May 5 (Reuters) - TG Therapeutics Inc:

* TG Therapeutics Inc provides business update and reports first quarter 2017 financial results

* Qtrly license revenue $38.1 million versus $38.1 million

* Qtrly loss per share $0.52

* TG Therapeutics - cash, cash equivalents, investment securities, and interest receivable will be sufficient to fund planned operations through 2018

* TG Therapeutics -cash,cash equivalents,investment securities, interest receivable $109.5 million as of March 31 to be sufficient to fund planned operations through 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below